New pill aims to wipe out lingering lymphoma cells after remission

NCT ID NCT07507318

Recruiting now Disease control Sponsor: Rong Tao Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests a drug called chidamide in people with a type of aggressive lymphoma (double-expressor DLBCL) who are in remission but still have traces of cancer DNA in their blood. The goal is to see if taking chidamide pills for up to two years can clear those hidden cancer cells and improve long-term outcomes. About 69 adults will take part across multiple hospitals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Chidamide (a type of targeted cancer pill)
What this could lead to: If successful, this could offer a way to eliminate hidden cancer cells after initial treatment, potentially delaying or preventing relapse in high-risk lymphoma patients.
What could go wrong: This is a small, early-phase study with no control group, so results may not be definitive. Chidamide can cause side effects like low blood counts and fatigue, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 20000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.